The FDA has approved Zevaskyn (prademagene zamikeracel) for the treatment of recessive dystrophic epidermolysis bullosa, a rare genetic skin disorder.

In a significant advancement for the Recessive Dystrophic Epidermolysis Bullosa (RDEB) community, the U.S. Food and Drug ...

The Florida Society of Clinical Oncology (FLASCO), a statewide organization dedicated to facilitating collaboration and ...

"I wanted to create an all-natural and delicious way to consume daily vitamins and minerals," said an inventor, from El Paso, Texas, "so I invented the VITAMIN BAR. My design would serve as a ...

Both gene therapies were approved as treatments for dystrophic epidermolysis bullosa, a rare and debilitating genetic skin condition.